Inhaled corticosteroids in COPD
88 results
1 - 88
Inhaled corticosteroids in COPD 
Inhaled corticosteroids increase pneumonia risk in stable COPD- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
- Corticosteroids benefit patients with moderate to severe COPD
- Inhaled corticosteroids and risk of fractures
- The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Inhaled steroids only decrease COPD exacerbations slightly
- Inhaled budesonide for COPD not associated with pneumonia
- Steroid inhalers increase fracture risk in COPD
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease: Cochrane systematic review
- Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
- Salmeterol + fluticasone better than tiotropium in COPD (INSPIRE)
- Chronic obstructive pulmonary disease (COPD)
- Low-dose theophylline is minimally helpful, if at all, in preventing COPD exacerbations
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
- Oral corticosteroids for stable chronic obstructive pulmonary disease
- USPSTF 2022: Recommendation against screening for chronic obstructive pulmonary disease (D recommendation)
- Inhaled corticosteroids for bronchiectasis: Cochrane systematic review
- Long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
- Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
- Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
- Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
- Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
- Vitamin D for the management of chronic obstructive pulmonary disease
- Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
- Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
- Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
- Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease